Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in BCR-Negative Myeloproliferative Disorders
NCT00136409Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2002
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in primary myelofibrosis (PMF), chronic myelomonocytic leukemia (CMML), sponsored by Dana-Farber Cancer Institute. Started May 2002; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00136409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136409.